Answers are grounded in this paper and cite their sources.
Background. Severe shock hails a dismal prognosis for patients in intensive care units. Vasoplegic patients, refractory to adrenergic catecholamines face an increased risk for in-hospital mortality. However, the optimal timing for Methylene Blue (MB) in these vasopressor-resistant patients, remains unclear. Methods. This was a retrospective, single-center study conducted in the intensive care unit (ICU) of a tertiary medical center. Results. 464 patients were included, 183 (39%) admitted to the general ICU and 281 (61%) to the cardiothoracic ICU. All patients developed vasoplegia and were treated with MB after a median time of 11.2 hours from admission. In the aggregated cohort, earlier MB administration was associated with lower ICU mortality (30% vs. 52%, p < 0.001), lower in-hospital mortality (41% vs. 59%, p < 0.001), lower 1-year mortality (46% vs. 62%, p < 0.001), and reduced need for continuous Veno venous hemofiltration (33% vs. 53%, p < 0.001). In survival analyses of the whole cohort, earlier MB administration was associated with reduced in-hospital mortality in univariate analysis (HR = 0.64; 95% CI 0.47–0.86, p = 0.003) and remained significant after multivariable adjustment (HR = 0.69; 95% CI 0.51–0.94, p = 0.018). ICU-specific analyses attenuated the association. Conclusions. In this retrospective, single-center cohort, earlier administration of MB was associated with improved clinical outcomes among ICU patients treated for vasoplegia, including lower mortality and reduced need for renal replacement therapy. Prospective studies are warranted to determine whether earlier MB administration should be incorporated into treatment protocols for adrenergic vasopressor-resistant vasoplegia.
No takes yet. Share an insight, caveat, or question.
Cohen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: